Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
Clinical trial NCT05267392 · UNKNOWN
Trial details
- NCT number
- NCT05267392
- Sponsor
- Instituto Portugues de Oncologia, Francisco Gentil, Porto
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-16
- Primary completion
- 2023-07-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.